The Million-Dollar Prescription: How Orphan Drugs Are Redefining Employer Risk

The Million-Dollar Prescription: How Orphan Drugs Are Redefining Employer Risk. One employee, one prescription, and a decision that can affect a health plan strategy for the year ahead. A moment like this is one that many employers are encountering as specialized therapies become increasingly available.

In Benefits Architecture: Understanding the Life of a Medical Claim, we examine how claims move through a benefits plan. Even cases that seem straightforward, like treatment for emergency appendicitis, can involve multiple administrative and financial steps. Orphan conditions, however, can follow a much more complex and unpredictable path that requires careful plan management.

What is an orphan medical condition, and what are orphan drugs?

An orphan medical condition or rare disease affects a relatively small portion of the population. In the United States, a condition is classified as an orphan if it impacts fewer than 200,000 individuals. Many of these conditions are genetic, chronic, and life-threatening, often requiring highly specialized, long-term care and medication.

Orphan drugs are medications designed to treat rare diseases. Developing these medications and treatments is often financially risky for pharmaceutical companies because the patient populations are small. To help, the federal government introduced the Orphan Drug Act in 1983, which allows companies to apply for orphan drug designation with the FDA. Approved drugs can qualify for research grants and tax credits for clinical trials, among other benefits.

These incentives have helped increase the development of life-changing therapies, but they also create a unique pricing dynamic. With few competitors and high costs spread across a small patient population, orphan drugs often come with exceptionally high price tags.

Life-saving treatments can come at a high cost.

Whether it’s a one-time, high-cost therapy or a lifelong treatment, the cost of orphan drugs can vary widely from patient to patient and can have a major impact on a health plan. Consider the following well-known orphan drugs, the conditions they treat and their typical costs:  

• Spinraza (nusinersen) treats spinal muscular atrophy (SMA). Approximate cost: ~$750,000 in the first year and ~$350,000–$375,000 annually thereafter.
• Zolgensma (onasemnogene abeparvovec) is a one-time gene therapy for spinal muscular atrophy. Approximate cost: ~$2.1–$2.25 million for a single treatment.
• Soliris (eculizumab) treats rare blood disorders such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Approximate cost: often exceeds ~$500,000 annually.
• Luxturna (voretigene neparvovec) treats a rare inherited retinal disease causing vision loss. Approximate cost: ~$850,000 per treatment ($425,000 per eye).
• Naglazyme (galsulfase) treats Maroteaux-Lamy syndrome (MPS VI). Approximate cost: typically ~$300,000–$400,000 annually.
• Elaprase (idursulfase) treats Hunter syndrome. Approximate cost: often ~$500,000+ annually, depending on patient size and dosing.

The cost reality for employers.

As the FDA continues to approve new therapies, and with many more awaiting approval, employers need to take a proactive approach. Costs can range from thousands to millions of dollars per treatment; even one claim of this size can increase premiums, make annual costs unpredictable, and put added pressure on stop-loss coverage.

Employers need to explore strategies that help keep costs sustainable over time while still supporting those employees who need access to these life-changing therapies. Here are some ways employers are navigating the risk:

1. Optimize stop-loss coverage. Ensure stop-loss policies are structured to reflect your organization’s risk tolerance, including appropriate specific and aggregate limits. Regularly review laser provisions and emerging exclusions tied to high-cost therapies.

1. Implement specialty drug management programs.  Develop targeted programs to manage the use and cost of specialty therapies, including orphan drugs and advanced treatments like gene therapy. Strategies can include prior authorization, clinical review, and site-of-care optimization.

1. Explore alternative funding solutions. Consider innovative strategies such as gene therapy risk-sharing arrangements, outcomes-based contracts, and specialty carve-out programs to help manage exposure to ultra-high-cost claims. These solutions can improve the predictability of plan expenses and provide flexibility for new treatments.

1. Increase transparency and data analytics. Use data insights to gain visibility into high-cost claims, monitor trends, and identify early risk signals. Increased transparency can help uncover opportunities for cost containment, support more accurate financial planning, and enable proactive decision-making.

1. Educate employees and promote advocacy. Provide employees with clear information about high-cost therapies, coverage options, and available support programs, helping employees make informed decisions while improving health outcomes and ensuring appropriate utilization of high-cost therapies.

1. Consider strategic plan exclusions with alternative pathways. As more orphan drugs gain FDA approval, some employers are considering the exclusion of ultra-high-cost therapies as part of a broader risk management strategy. When carefully implemented, this approach can include support to help affected employees access alternative funding sources, such as manufacturer assistance programs, charitable organizations, or public benefits where eligible. Careful compliance oversight and close collaboration with a trusted benefits specialist, along with attention to employee experience, are essential to making this strategy work effectively.

While the number of affected individuals may be small, the impact on a health plan can be substantial.

With the right combination of insight, planning, and strategic partnerships, employers can avoid unexpected high costs while continuing to support employees who rely on these life-changing therapies.

If you have questions about managing orphan drugs or optimizing your plan’s approach, reach out today.

Cost figures, coverage details, and plan design elements presented in this blog are for illustrative purposes only and do not reflect any specific insurance policy or provider. Actual costs will vary based on your organization’s health plan, the insurance carrier, provider contracts, and the specifics of each medical situation. Employers and employees should refer to their official plan documents or speak with their broker or benefits consultant for guidance if needed.